BTIG analyst Kaveri Pohlman raised the firm’s price target on Cullinan Therapeutics to $30 from $20 and keeps a Buy rating on the shares. The firm is citing Cullinan’s recent corporate update since CLN-978’s drug development plans in the SLE, or systemic lupus erythematosus, space that alone is offering an $11B market opportunity. BTIG further notes Cullinan has plans to open clinical trials for CLN-978 in other autoimmune disease indications.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGEM:
- Cullinan Management’s Strategic Shift and Capital Raise
- Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
- Cullinan Therapeutics announces oversubscribed $280M private placement
- Cullinan initiated with Outperform on oncology portfolio at William Blair
- Cullinan Oncology initiated with an Outperform at William Blair
